Use of silver in the prevention and treatment of infections: Silver review

Surgical Infections

Volumn 14, Issue 1, 2013, Pages 8-20

  Politano, Amani D ^a   Campbell, Kristin T ^a   Rosenberger, Laura H ^a   Sawyer, Robert G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILVER; SILVER NITRATE; SULFADIAZINE SILVER;

ANTIMICROBIAL THERAPY; ARGYRIA; ARTIFICIAL VENTILATION; BACTERICIDAL ACTIVITY; BACTERIUM CONTAMINATION; BLOOD VESSEL PROSTHESIS; BURN; CATHETER INFECTION; COST EFFECTIVENESS ANALYSIS; DEVICE INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ENDOTRACHEAL TUBE; EYE INFECTION; HEALTH CARE COST; HEART VALVE PROSTHESIS; HEMOLYTIC ANEMIA; HISTORY OF MEDICINE; HUMAN; INCISION; INFECTION; INFECTION PREVENTION; MECHANICAL VENTILATOR; NEISSERIACEAE INFECTION; NEWBORN INFECTION; NONHUMAN; ORTHOPEDIC EQUIPMENT; PRIORITY JOURNAL; PROSTHESIS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOPICAL TREATMENT; ULCER; URINARY CATHETER; URINARY TRACT INFECTION; WOUND DRESSING; WOUND INFECTION;

BACTERIAL INFECTIONS; HEART VALVE PROSTHESIS; HUMANS; PROSTHESIS-RELATED INFECTIONS; SILVER; SILVER COMPOUNDS; URINARY TRACT INFECTIONS; WOUND INFECTION;

EID: 84875153700     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.097     Document Type: Review

References (188)

1. Alexander JW. History of the medical use of silver. Surg Infect 2009;10:289-292.
2. Klasen HJ. Historical review of the use of silver in the treatment of burns I: Early uses. Burns 2000;26:117-130.
3. Klasen HJ. A historical review of the use of silver in the treatment of burns II: Renewed interest for silver. Burns 2000;26:131-138.
4. Reid MR, Zinninger MM, Merrell P. Closure of the abdomen with through-And-through silver wire sutures in cases of acute abdominal emergencies. Ann Surg 1933;98:890-896.
5. Rucker MP. Silver sutures. Bull Hist Med 1950;24:190-192.
6. Clement JL, Jarrett PS. Antibacterial silver. Met Based Drugs 1994;1:467-482.
7. Fox CL Jr, Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother 1974;5:582-588.
8. Monafo WW. The management of burns II: The silver nitrate method. Curr Probl Surg 1969;Feb:53-66.
9. Feng QL, Wu J, Chen GQ, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000;52: 662-668.
10. Rosenkranz HS, Rosenkranz S. Silver sulfadiazine: Interaction with isolated deoxyribonucleic acid. Antimicrob Agents Chemother 1972;2:373-383.
11. Jung WK, Koo HC, Kim KW, et al. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol 2008;74: 2171-2178.
12. Gordon O, Vig Slenters T, Brunetto PS, et al. Silver coordination polymers for prevention of implant infection: Thiol interaction, impact on respiratory chain enzymes, and hydroxyl radical induction. Antimicrob Agents Chemother 2010;54:4208-4218.
13. Schreurs WJ, Rosenberg H. Effect of silver ions on transport and retention of phosphate by Escherichia coli. J Bacteriol 1982;152:7-13.
14. Ricketts CR, Lowbury EJ, Lawrence JC, et al. Mechanism of prophylaxis by silver compounds against infection of burns. Br Med J 1970;1(5707):444-446.
15. Dunn K, Edwards-Jones V. The role of Acticoat with na-nocrystalline silver in the management of burns. Burns 2004;30(Suppl 1):S1-S9.
16. Kim JS, Kuk E, Yu KN, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007;3:95-101.
17. Pal S, Tak YK, Joardar J, et al. Nanocrystalline silver supported on activated carbon matrix from hydrosol: Antibacterial mechanism under prolonged incubation conditions. J Nanosci Nanotechnol 2009;9:2092-2103.
18. Li WR, Xie XB, Shi QS, et al. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol 2010;85:1115-1122.
19. Xu H, Qu F, Xu H, et al. Role of reactive oxygen species in the antibacterial mechanism of silver nanoparticles on Es-cherichia coli O157:H7. Biometals 2011;25:45-53.
20. Morones JR, Elechiguerra JL, Camacho A, et al. The bactericidal effect of silver nanoparticles. Nanotechnology 2005;16:2346-2353.
21. Fox CL Jr. Silver sulfadiazine-A new topical therapy for Pseudomonas in burns. Arch Surg 1968;96:184-188.
22. Stanford W, Rappole BW, Fox CL Jr. Clinical experience with silver sulfadiazine, a new topical agent for control of Pseudomonas infections in burns. J Trauma 1969;9: 377-388.
23. Monafo WW, Moyer CA. The treatment of extensive thermal burns with 0.5 per cent silver nitrate solution. Ann NY Acad Sci 1968;150:937-945.
24. Price WR, Wood M. Treatment of the infected burn with dilute silver nitrate solution. Am J Surg 1967;114:641-647.
25. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns 2007;33:139-148.
26. Helvig EI, Munster AM, Su CT, Oppel W. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: A prospective, randomized study. Am Surg 1979;45:270-272.
27. Munster AM, Helvig E, Rowland S. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: A prospective evaluation. Surgery 1980;88:658-660.
28. Bowser BH, Caldwell FT, Cone JB, et al. A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children. J Trauma 1981;21:558-563.
29. de Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns 2001;27:67-74.
30. Inman RJ, Snelling CF, Roberts FJ, et al. Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection. Burns Incl Therm Inj 1984;11:35-40.
31. Snelling CF, Inman RJ, Germann E, et al. Comparison of silver sulfadiazine 1% with chlorhexidine digluconate 0.2% to silver sulfadiazine 1% alone in the prophylactic topical antibacterial treatment of burns. J Burn Care Rehabil 1991;12:13-18.
32. Fraser JF, Bodman J, Sturgess R, et al. An in vitro study of the anti-microbial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulpha-diazine cream and a silver coated dressing. Burns 2004;30:35-41.
33. Gray JH, Henry DA, Forbes M, et al. Comparison of silver sulphadiazine 1 per cent, silver sulphadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent and mafenide acetate 8.5 per cent for topical antibacterial effect in infected full skin thickness rat burn wounds. Burns 1991; 17:37-40.
34. Koller J. Topical treatment of partial thickness burns by silver sulfadiazine plus hyaluronic acid compared to silver sulfadiazine alone: A double-blind, clinical study. Drugs Exp Clin Res 2004;30:183-190.
35. Costagliola M, Agros̀i M. Second-degree burns: A comparative, multicenter, randomized trial of hyaluronic acid plus silver sulfadiazine vs. silver sulfadiazine alone. Curr Med Res Opin 2005;21:1235-1240.
36. Leaper DJ. Silver dressings: Their role in wound management. Int Wound J 2006;3:282-294.
37. Cutting K, White R, Hoekstra H. Topical silver-impregnated dressings and the importance of the dressing technology. Int Wound J 2009;6:396-402.
38. Fong J, Wood F. Nanocrystalline silver dressings in wound management: A review. Int J Nanomedicine 2006;1: 441-449.
39. Deitch EA, Marino AA, Malakanok V, Albright JA. Silver nylon cloth: In vitro and in vivo evaluation of antimicrobial activity. J Trauma 1987;27:301-304.
40. Gravante G, Caruso R, Sorge R, et al. Nanocrystalline silver: A systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Ann Plast Surg 2009;63:201-205.
41. Falcone AE, Spadaro JA. Inhibitory effects of electrically activated silver material on cutaneous wound bacteria. Plast Reconstr Surg 1986;77:455-459.
42. Becker RO, Spadaro JA. Treatment of orthopaedic infections with electrically generated silver ions: A preliminary report. J Bone Joint Surg Am 1978;60:871-881.
43. Chu CS, McManus AT, Pruitt BA Jr, Mason AD Jr. Therapeutic effects of silver nylon dressings with weak direct current on Pseudomonas aeruginosa-infected burn wounds. J Trauma 1988;28:1488-1492.
44. Chu CS, McManus AT, Mason AD, Pruitt BA Jr. Topical silver treatment after escharectomy of infected full thickness burn wounds in rats. J Trauma 2005;58:1040-1046.
45. Chu CS, Matylevich NP, McManus AT, et al. Optimized mesh expansion of composite skin grafts in rats treated with direct current. J Trauma 1997;43:804-811.
46. Chu CS, Matylevitch NP, McManus AT, et al. Accelerated healing with a mesh autograft/allodermal composite skin graft treated with silver nylon dressings with and without direct current in rats. J Trauma 2000;49:115-125.
47. Chu CS, McManus AT, Okerberg CV, et al. Weak direct current accelerates split-thickness graft healing on tangen-tially excised second-degree burns. J Burn Care Rehabil 1991;12:285-293.
48. Engrav LH, Heimbach DM, Reus JL, et al. Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: A randomized prospective study. J Trauma 1983;23:1001-1004.
49. Barret JP, Dziewulski P, Ramzy PI, et al. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg 2000;105:62-65.
50. Hosseini SN, Karimian A, Mousavinasab SN, et al. Xeno-derm versus 1% silver sulfadiazine in partial-thickness burns. Asian J Surg 2009;32:234-239.
51. Gerding RL, Emerman CL, Effron D, et al. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. Ann Emerg Med 1990;19:121-124.
52. Silverstein P, Heimbach D, Meites H, et al. An open, parallel, randomized, comparative, multicenter study to evaluate the cost-effectiveness, performance, tolerance, and safety of a silver-containing soft silicone foam dressing (intervention) vs silver sulfadiazine cream. J Burn Care Res 2011;32:617-626.
53. Fong J, Wood F, Fowler B. A silver coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: Comparative patient care audits. Burns 2005;31:562-567.
54. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. Cochrane Database Syst Rev 2007;(1):CD005486.
55. Lo SF, Hayter M, Chang CJ, et al. A systematic review of silver-releasing dressings in the management of infected chronic wounds. J Clin Nurs 2008;17:1973-1985.
56. Chambers H, Dumville JC, Cullum N. Silver treatments for leg ulcers: A systematic review. Wound Repair Regen 2007;15:165-173.
57. Lo SF, Chang CJ, Hu WY, et al. The effectiveness of silver-releasing dressings in the management of non-healing chronic wounds: A meta-Analysis. J Clin Nurs 2009;18: 716-728.
58. Carter MJ, Tingley-Kelley K, Warriner RA 3rd. Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: A systematic review and meta-Analysis. J Am Acad Dermatol 2010;63:668-679.
59. Michaels JA, Campbell B, King B, et al. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). Br J Surg 2009;96:1147-1156.
60. Scanlon E, Karlsmark T, Leaper DJ, et al. Cost-effective faster wound healing with a sustained silver-releasing foam dressing in delayed healing leg ulcers: A health-economic analysis. Int Wound J 2005;2:150-160.
61. Wang J, Smith J, Babidge W, Maddern G. Silver dressings versus other dressings for chronic wounds in a community care setting. J Wound Care 2007;16:352-356.
62. Jørgensen B, Price P, Andersen KE, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: A randomised, controlled trial. Int Wound J 2005;2:64-73.
63. Münter KC, Beele H, Russell L, et al. Effect of a sustained silver-releasing dressing on ulcers with delayed healing: The CONTOP study. J Wound Care 2006;15:199-206.
64. Totaro P, Rambaldini M. Efficacy of antimicrobial activity of slow release silver nanoparticles dressing in post-cardiac surgery mediastinitis. Interact Cardiovasc Thorac Surg 2009;8:153-154.
65. Huckfeldt R, Redmond C, Mikkelson D, et al. A clinical trial to investigate the effect of silver nylon dressings on mediastinitis rates in postoperative cardiac sternotomy incisions. Ostomy Wound Manage 2008;54:36-41.
66. Krieger BR, Davis DM, Sanchez JE, et al. The use of silver nylon in preventing surgical site infections following colon and rectal surgery. Dis Colon Rectum 2011;54:1014-1019.
67. Childress BB, Berceli SA, Nelson PR, et al. Impact of an absorbent silver-eluting dressing system on lower extremity revascularization wound complications. Ann Vasc Surg 2007;21:598-602.
68. Innes ME, Umraw N, Fish JS, et al. The use of silver coated dressings on donor site wounds: A prospective, controlled matched pair study. Burns 2001;27:621-627.
69. Lohsiriwat V, Chuangsuwanich A. Comparison of the ionic silver-containing hydrofiber and paraffin gauze dressing on split-thickness skin graft donor sites. Ann Plast Surg 2009;62:421-422.
70. Payne JL, Ambrosio AM. Evaluation of an antimicrobial silver foam dressing for use with V.A.C. Therapy: Morphological, mechanical, and antimicrobial properties. J Biomed Mater Res B Appl Biomater 2009;89:217-222.
71. Gerry R, Kwei S, Bayer L, Breuing KH. Silver-impregnated vacuum-Assisted closure in the treatment of recalcitrant venous stasis ulcers. Ann Plast Surg 2007;59:58-62.
72. Cohen MS, Stern JM, Vanni AJ, et al. In vitro analysis of a nanocrystalline silver-coated surgical mesh. Surg Infect 2007;8:397-403.
73. Chu CC, Tsai WC, Yao JY, Chiu SS. Newly made antibacterial braided nylon sutures I: In vitro qualitative and in vivo preliminary biocompatibility study. J Biomed Mater Res 1987;21:1281-1300.
74. Pratten J, Nazhat SN, Blaker JJ, Boccaccini AR. In vitro attachment of Staphylococcus epidermidis to surgical sutures with and without Ag-containing bioactive glass coating. J Biomater Appl 2004;19:47-57.
75. Blaker JJ, Nazhat SN, Boccaccini AR. Development and characterisation of silver-doped bioactive glass-coated sutures for tissue engineering and wound healing applications. Biomaterials 2004;25:1319-1329.
76. Renaud B, Brun-Buisson C; ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia: A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001;163:1584-1590.
77. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005;41:1591-1598.
78. Warren DK, Quadir WW, Hollenbeak CS, et al. Attributable cost of catheter-Associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 2006;34:2084-2089.
79. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-1601.
80. Dimick JB, Pelz RK, Consunji R, et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001;136: 229-234.
81. O'Grady NP, Alexander M, Burns LA, et al; Healthcare Infection Control Practices Advisory Committee (HIC-PAC). Summary of recommendations: Guidelines for the Prevention of Intravascular Catheter-Related Infections. Clin Infect Dis 2011;52:1087-1099.
82. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-2732.
83. Dünser MW, Mayr AJ, Hinterberger G, et al. Central venous catheter colonization in critically ill patients: A prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. An-esth Analg 2005;101:1778-1784.
84. Bach A, Eberhardt H, Frick A, et al. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Crit Care Med 1999;27:515-521.
85. Corral L, Nolla-Salas M, Ibañez-Nolla J, et al. A prospective, randomized study in critically ill patients using the Oligon Vantex catheter. J Hosp Infect 2003;55:212-219.
86. Moretti EW, Ofstead CL, Kristy RM, Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. J Hosp Infect 2005;61: 139-145.
87. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: A randomized, controlled trial. Ann Intern Med 1997;127:257-266.
88. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhex-idine and silver sulfadiazine on central catheter-related infections: A randomized, controlled trial. Ann Intern Med 2005;143:570-580.
89. Casey AL, Mermel LA, Nightingale P, Elliott TS. Antimicrobial central venous catheters in adults: A systematic review and meta-Analysis. Lancet Infect Dis 2008;8: 763-776.
90. Wang H, Huang T, Jing J, et al. Effectiveness of different central venous catheters for catheter-related infections: A network meta-Analysis. J Hosp Infect 2010;76:1-11.
91. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999;340:1-8.
92. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-Analysis. JAMA 1999;281:261-267.
93. Schuerer DJ, Zack JE, Thomas J, et al. Effect of chlorhex-idine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: A before-After trial. Surg Infect 2007;8:445-454.
94. Camargo LF, Marra AR, Büchele GL, et al. Double-lumen central venous catheters impregnated with chlorhexidine and silver sulfadiazine to prevent catheter colonisation in the intensive care unit setting: A prospective randomised study. J Hosp Infect 2009;72:227-233.
95. Kalfon P, de Vaumas C, Samba D, et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med 2007;35:1032-1039.
96. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282:554-560.
97. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: Potential financial implications. Chest 2003;124:275-284.
98. Akiyama H, Okamoto S. Prophylaxis of indwelling urethral catheter infection: Clinical experience with a modified Foley catheter and drainage system. J Urol 1979;121:40-42.
99. Liedberg H, Lundeberg T, Ekman P. Refinements in the coating of urethral catheters reduces the incidence of catheter-Associated bacteriuria: An experimental and clinical study. Eur Urol 1990;17:236-240.
100. Liedberg H, Lundeberg T. Silver alloy coated catheters reduce catheter-Associated bacteriuria. Br J Urol 1990;65: 379-381.
101. Karchmer TB, Giannetta ET, Muto CA, et al. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. Arch Intern Med 2000;160:3294-3298.
102. Thibon P, Le Coutour X, Leroyer R, Fabry J. Randomized multi-centre trial of the effects of a catheter coated with hydrogel and silver salts on the incidence of hospital-Acquired urinary tract infections. J Hosp Infect 2000;45: 117-124.
103. Bologna RA, Tu LM, Polansky M, et al. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: A multicenter study. Urology 1999;54:982-987.
104. Riley DK, Classen DC, Stevens LE, Burke JP. A large randomized clinical trial of a silver-impregnated urinary catheter: Lack of efficacy and staphylococcal superinfec-tion. Am J Med 1995;98:349-356.
105. Srinivasan A, Karchmer T, Richards A, et al. A prospective trial of a novel, silicone-based, silver-coated Foley catheter for the prevention of nosocomial urinary tract infections. Infect Control Hosp Epidemiol 2006;27:38-43.
106. Schaeffer AJ, Story KO, Johnson SM. Effect of silver oxide/ trichloroisocyanuric acid antimicrobial urinary drainage system on catheter-Associated bacteriuria. J Urol 1988;139: 69-73.
107. Johnson JR, Roberts PL, Olsen RJ, et al. Prevention of catheter-Associated urinary tract infection with a silver oxide-coated urinary catheter: Clinical and microbiologic correlates. J Infect Dis 1990;162:1145-1150.
108. Saint S, Elmore JG, Sullivan SD, et al. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: A meta-Analysis. Am J Med 1998;105:236-241.
109. Rupp ME, Fitzgerald T, Marion N, et al. Effect of silver-coated urinary catheters: Efficacy, cost-effectiveness, and antimicrobial resistance. Am J Infect Control 2004;32: 445-450.
110. Schumm K, Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev 2008;(2):CD004013.
111. Reiche T, Lisby G, Jørgensen S, et al. A prospective, controlled, randomized study of the effect of a slow-release silver device on the frequency of urinary tract infection in newly catheterized patients. BJU Int 2000;85:545-549.
112. Huth TS, Burke JP, Larsen RA, et al. Randomized trial of metal care with silver sulfadiazine cream for the prevention of catheter-Associated bacteriuria. J Infect Dis 1992;165: 14-18.
113. Daifuku R, Stamm WE. Association of rectal and urethral colonization with urinary tract infection in patients with indwelling catheters. JAMA 1984;252:2028-2030.
114. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485.
115. Hugonnet S, Eggimann P, Borst F, et al. Impact of ventilator-Associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004;25: 1090-1096.
116. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-Associated pneumonia: A systematic review. Crit Care Med 2005;33:2184-2193.
117. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-Associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:1312-1317.
118. Institute for Healthcare Improvement. Available at http://www.ihi.org. Accessed July 29, 2011.
119. Efrati S, Deutsch I, Antonelli M, et al. Ventilator-Associated pneumonia: Current status and future recommendations. J Clin Monit Comput 2010;24:161-168.
120. Doyle A, Fletcher A, Carter J, et al. The incidence of ventilator-Associated pneumonia using the PneuX System with or without elective endotracheal tube exchange: A pilot study. BMC Res Notes 2011;4:92.
121. Kollef MH, Afessa B, Anzueto A, et al; NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of ventilator-Associated pneumonia: The NASCENT randomized trial. JAMA 2008;300:805-813.
122. Lacherade JC, De Jonghe B, Guezennec P, et al. Intermittent subglottic secretion drainage and ventilator-Associated pneumonia: A multicenter trial. Am J Respir Crit Care Med 2010;182:910-917.
123. Asai T, Shingu K. Leakage of fluid around high-volume, low-pressure cuffs apparatus: A comparison of four tra-cheal tubes. Anaesthesia 2001;56:38-42.
124. Berra L, Kolobow T, Laquerriere P, et al. Internally coated endotracheal tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: A clinical trial. Intensive Care Med 2008;34:1030-1037.
125. Rello J, Afessa B, Anzueto A, et al. Activity of a silver-coated endotracheal tube in preclinical models of ventilator-Associated pneumonia and a study after extubation. Crit Care Med 2010;38:1135-1140.
126. Olson ME, Harmon BG, Kollef MH. Silver-coated endo-tracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest 2002;121:863-870.
127. Rello J, Kollef M, Diaz E, et al. Reduced burden of bacterial airway colonization with a novel silver-coated endotra-cheal tube in a randomized multiple-center feasibility study. Crit Care Med 2006;34:2766-2772.
128. Palmore TN, Henderson DK. Testing the tube: Assessing silver as a potential "silver bullet" for preventing ventilator-Associated pneumonia. Crit Care Med 2010;38: 1220-1221.
129. Afessa B, Shorr AF, Anzueto AR, et al. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-Associated pneumonia. Chest 2010;137:1015-1021.
130. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-Associated pneumonia in determining patient mortality. Chest 1995;108:1655-1662.
131. Shorr AF, Zilberberg MD, Kollef M. Cost-effectiveness analysis of a silver-coated endotracheal tube to reduce the incidence of ventilator-Associated pneumonia. Infect Control Hosp Epidemiol 2009;30:759-763.
132. Klompas M. Silver-coated endotracheal tubes and patient outcomes in ventilator-Associated pneumonia. JAMA 2008;300:2605.
133. Resar R, Pronovost P, Haraden C, et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-Associated pneumonia. Jt Comm J Qual Patient Saf 2005;31:243-248.
134. Zilberberg MD, Shorr AF, Kollef MH. Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. Crit Care Med 2009;37:305-309.
135. Wassall MA, Santin M, Isalberti C, et al. Adhesion of bacteria to stainless steel and silver-coated orthopedic external fixation pins. J Biomed Mater Res 1997;36:325-330.
136. Collinge CA, Goll G, Seligson D, Easley KJ. Pin tract infections: Silver vs uncoated pins. Orthopedics 1994;17: 445-448.
137. Bosetti M, Massè A, Tobin E, Cannas M. Silver coated materials for external fixation devices: In vitro biocompat-ibility and genotoxicity. Biomaterials 2002;23:887-992.
138. Massè A, Bruno A, Bosetti M, et al. Prevention of pin track infection in external fixation with silver coated pins: Clinical and microbiological results. J Biomed Mater Res 2000; 53:600-604.
139. Yuenyongviwat V, Tangtrakulwanich B. Prevalence of pin-site infection: The comparison between silver sulfadiazine and dry dressing among open tibial fracture patients. J Med Assoc Thai 2011;94:566-569.
140. Ogbemudia AO, Bafor A, Edomwonyi E, Enemudo R. Prevalence of pin tract infection: The role of combined silver sulphadiazine and chlorhexidine dressing. Niger J Clin Pract 2010;13:268-271.
141. Das K, Bose S, Bandyopadhyay A, et al. Surface coatings for improvement of bone cell materials and antimicrobial activities of Ti implants. J Biomed Mater Res B Appl Bio-mater 2008;87:455-460.
142. Zhao L, Wang H, Huo K, et al. Antibacterial nano-struc-tured titania coating incorporated with silver nanoparticles. Biomaterials 2011;32:5706-5716.
143. Khalilpour P, Lampe K, Wagener M, et al. Ag/SiO(x)C(y) plasma polymer coating for antimicrobial protection of fracture fixation devices. J Biomed Mater Res B Appl Bio-mater 2010;94:196-202.
144. Sheehan E, McKenna J, Mulhall KJ, et al. Adhesion of Sta-phylococcus to orthopaedic metals: An in vivo study. J Or-thop Res 2004;22:39-43.
145. Hardes J, von Eiff C, Streitbuerger A, et al. Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 2010;101:389-395.
146. Hardes J, Ahrens H, Gebert C, et al. Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials 2007;28:2869-2875.
147. Pupka A, Skora J, Janczak D, et al. In situ revascularisation with silver-coated polyester prostheses and arterial homo-grafts in patients with aortic graft infection: A prospective, comparative, single-centre study. Eur J Vasc Endovasc Surg 2011;41:61-67.
148. Batt M, Magne JL, Alric P, et al. In situ revascularization with silver-coated polyester grafts to treat aortic infection: Early and midterm results. J Vasc Surg 2003;38:983-989.
149. Batt M, Jean-Baptiste E, O'Connor S, et al. In-situ re-vascularisation for patients with aortic graft infection: A single centre experience with silver coated polyester grafts. Eur J Vasc Endovasc Surg 2008;36:182-188.
150. Ricco JB; InterGard Silver Study Group. InterGard silver bifurcated graft: Features and results of a multicenter clinical study. J Vasc Surg 2006;44:339-346.
151. Larena-Avellaneda A, Russmann S, Fein M, Debus ES. Prophylactic use of the silver-Acetate-coated graft in arterial occlusive disease: A retrospective, comparative study. J Vasc Surg 2009;50:790-798.
152. Tautenhahn J, Meyer F, Buerger T, et al. Interactions of neutrophils with silver-coated vascular polyester grafts. Langenbecks Arch Surg 2010;395:143-149.
153. Illingworth BL, Tweden K, Schroeder RF, Cameron JD. In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis. J Heart Valve Dis 1998;7:524-530.
154. Illingworth B, Bianco RW, Weisberg S. In vivo efficacy of silver-coated fabric against Staphylococcus epidermidis. J Heart Valve Dis 2000;9:135-141.
155. Darouiche RO, Meade R, Mansouri M, Raad II. In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings. J Heart Valve Dis 1998;7:639-646.
156. Schaff H, Carrel T, Steckelberg JM, et al. Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial. J Heart Valve Dis 1999;8: 131-139.
157. Brutel De La Riviere A, Dossche KM, Birnbaum DE, Hacker R. First clinical experience with a mechanical valve with silver coating. J Heart Valve Dis 2000;9:123-129.
158. Carrel T, Nguyen T, Kipfer B, Althaus U. Definitive cure of recurrent prosthetic endocarditis using silver-coated St. Jude Medical heart valves: A preliminary case report. J Heart Valve Dis 1998;7:531-533.
159. Bertrand S, Houel R, Vermes E, et al. Preliminary experience with Silzone-coated St. Jude Medical valves in acute infective endocarditis. J Heart Valve Dis 2000;9:131-134.
160. Auer J, Berent R, Ng CK, et al. Early investigation of silver-coated Silzone heart valves prosthesis in 126 patients. J Heart Valve Dis 2001;10:717-723.
161. Kjaergard HK, Tingleff J, Abildgaard U, Pettersson G. Recurrent endocarditis in silver-coated heart valve prosthesis. J Heart Valve Dis 1999;8:140-142.
162. Ionescu A, Payne N, Fraser AG, et al. Incidence of embolism and paravalvar leak after St. Jude Silzone valve implantation: Experience from the Cardiff Embolic Risk Factor Study. Heart 2003;89:1055-1061.
163. Dávila-Román VG, Waggoner AD, Kennard ED, et al; Artificial Valve Endocarditis Reduction Trial Echocardio-graphy Study. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) Echocardiography Study. J Am Coll Cardiol 2004;44:1467-1472.
164. Schaff HV, Carrel TP, Jamieson WR, et al; Artificial Valve Endocarditis Reduction Trial. Paravalvular leak and other events in Silzone-coated mechanical heart valves: A report from AVERT. Ann Thorac Surg 2002;73:785-792.
165. Jamieson WR, Fradet GJ, Abel JG, et al. Seven-year results with the St. Jude Medical Silzone mechanical prosthesis. J Thorac Cardiovasc Surg 2009;137:1109-1115.
166. Grunkemeier GL, Jin R, Im K, et al. Time-related risk of the St. Jude Silzone heart valve. Eur J Cardiothorac Surg 2006;30:20-27.
167. Herijgers P, Herregods MC, Vandeplas A, et al. Silzone coating and paravalvular leak: An independent, randomized study. J Heart Valve Dis 2001;10:712-715.
168. Stalenhoef JE, Mellema EC, Veeger NJ, Ebels T. Thrombo-genicity and reoperation of the St. Jude Medical Silzone valve: A comparison with the conventional St. Jude Medical valve. J Heart Valve Dis 2003;12:635-639.
169. Dandekar UP, Baghai M, Kalkat M, Ridley PD. Silzone-coated St. Jude Medical valves: Six-year experience in 46 patients. J Heart Valve Dis 2007;16:37-41.
170. Butany J, Leask RL, Desai ND, et al. Pathologic analysis of 19 heart valves with silver-coated sewing rings. J Card Surg 2006;21:530-538.
171. Seipelt RG, Vazquez-Jimenez JF, Seipelt IM, et al. The St. Jude "Silzone" valve: Midterm results in treatment of active endocarditis. Ann Thorac Surg 2001;72:758-762.
172. Rosenman KD, Moss A, Kon S. Argyria: Clinical implications of exposure to silver nitrate and silver oxide. J Occup Med 1979;21:430-435.
173. Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res 2009;30:464-470.
174. Coombs CJ, Wan AT, Masterton JP, et al. Do burn patients have a silver lining? Burns 1992;18:179-184.
175. Bader KF. Organ deposition of silver following silver nitrate therapy of burns. Plast Reconstr Surg 1966;37:550-551.
176. Wan AT, Conyers RA, Coombs CJ, Masterton JP. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem 1991;37:1683-1687.
177. Iwasaki S, Yoshimura A, Ideura T, et al. Elimination study of silver in a
178. Lansdown AB. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol 2007;37:237-250.
179. Trop M, Novak M, Rodl S, et al. Silver-coated dressing Acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 2006;60:648-652.
180. Vlachou E, Chipp E, Shale E, et al. The safety of nano-crystalline silver dressings on burns: A study of systemic silver absorption. Burns 2007;33:979-985.
181. Eldad A, Neuman A, Weinberg A, et al. Silver sulphadia-zine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns 1991;17: 430-432.
182. Choban PS, Marshall WJ. Leukopenia secondary to silver sulfadiazine: Frequency, characteristics and clinical consequences. Am Surg 1987;53:515-517.
183. Fuller FW, Engler PE. Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: A survey. J Burn Care Rehabil 1988;9:606-609.
184. Gamelli RL, Paxton TP, O'Reilly M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet 1993;177: 115-120.
185. Fraser-Moodie A. Sensitivity to silver in a patient treated with silver sulphadiazine (Flamazine). Burns 1992;18: 74-75.
186. Poon VK, Burd A. In vitro cytotoxity of silver: Implication for clinical wound care. Burns 2004;30:140-147.
187. Cortese-Krott MM, Münchow M, Pirev E, et al. Silver ions induce oxidative stress and intracellular zinc release in human skin fibroblasts. Free Radic Biol Med 2009;47:1570-1577.
188. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol 2009;10:65.